(113) analyzed 43 randomized, controlled trials that met the following inclusion criteria: at least 52 weeks in duration, and comparison of a GLP1-RA versus any non–GLP1-RA treatment in patients with T2DM and PC. This evidence concerns the gene GCG and type 2 diabetes mellitus.